A Study of the Use of Quantiferon CMV Blood Test to Find the Length of CMV Prevention in CMV Donor (+) / Recipient (-) Solid Organ Transplant Recipients

Overview

About this study

The overall aim of this study is to evaluate the clinical utility of the QuantiFERON-CMV test in solid organ transplant recipients on CMV prophylaxis to predict development of CMV disease after completion of prophylaxis. Our hypothesis is that in CMV D+/R- solid organ transplant recipients, the development of immunity as measured by a positive QuantiFERON CMV assay will predict a lower risk of CMV disease after prophylaxis is completed.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

Patients 18 years old or older that will receive a solid organ transplant at Mayo Clinic
Participants (recipients) must be negative for CMV serology prior to transplant.
Donor must be seropositive for CMV
Patients that give us consent to be enrolled in our study and to obtain a sample of blood for QuantiFERON-CMV testing, at the above mentioned points in time.

Exclusion criteria:

Lack of informed consent

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Raymund Razonable, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Raymund Razonable, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials